Skip to content

OST and MORES in Male Osteoporosis

Performance of the Osteoporosis Self-Assessment Tool (OST) and Male Osteoporosis Risk Estimate Score (MORES) in Predicting Osteoporosis in Turkish Men

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07518212
Acronym
OST and MORES
Enrollment
140
Registered
2026-04-08
Start date
2026-02-04
Completion date
2026-09-15
Last updated
2026-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male Osteoporosis

Keywords

male ostoporosis, OST, MORES, osteoporosis risk estimation

Brief summary

The aim of this study is to compare the Male Osteoporosis Risk Score and the Osteoporosis Self-Assessment Tool with the gold standard DEXA in determining the risk of osteoporosis in the lumbar and femoral regions in male individuals in the Turkish population, and to investigate their sensitivity and specificity in the first stage of screening for the detection of male osteoporosis.

Detailed description

This study will be conducted as a single-center, retrospective study at the Physical Medicine and Rehabilitation Clinic of Kayseri City Hospital between January 2024 and January 2025. Male patients aged 50-75 who underwent osteoporosis screening with DEXA between January 2021 and January 2024 at the FTR outpatient clinics of Kayseri City Hospital will be included in this study. Patient data will be obtained retrospectively from the hospital database. Sociodemographic data (age, height, weight, body mass index) and current laboratory data (complete blood count, biochemical values (fasting blood sugar, BUN, creatinine, AST, ALT, calcium, phosphorus, alkaline phosphatase, total protein, albumin, parathyroid hormone, vitamin D3, T4, TSH), and DEXA values (bone mineral density, lumbar vertebrae, and total T scores for the femoral neck and femur) will be recorded. The OST score will be calculated using body weight and age parameters. The MORES score will be calculated based on age, weight, and hospital data, specifically the presence of chronic obstructive pulmonary disease (COPD) with ICD-10 code: J44 and its subgroups. The data will be evaluated using the SPSS 24.0 software package. Descriptive statistical analyses will include calculations of mean, standard deviation, frequency, and percentages. In comparative statistics, the Student's t-test or Mann-Whitney U test will be used to compare independent groups. Chi-square analysis will be applied to compare categorical variables. Pearson or Spearman correlation analyses will be applied to evaluate the relationship between variables. Both groups will be compared, and p\<0.05 will be considered statistically significant.

Interventions

None listed

Sponsors

Kayseri City Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Men aged 50-75 * Patients who underwent imaging with the STRATOS DEXA device at Kayseri City Hospital

Exclusion criteria

* Patients younger than 50 or older than 75 years of age * Patients with secondary osteoporosis * Female patients * Patients with uncontrolled severe comorbid conditions * Patients with a history of pathological fractures

Design outcomes

Primary

MeasureTime frameDescription
Dual energy Xray Absorptiometry (DEXA)January 2021-January 2024DEXA measures bone mineral density (BMD; g/cm2) based on the scanned bone area. T and Z scores are used to interpret DEXA results. The T score indicates how many standard deviations below or above the average BMD measurements of a patient of the same gender and younger adults. The T score should be used for the diagnosis of osteoporosis in postmenopausal women and men over 50 years of age. The Z score indicates how many standard deviations below or above the average BMD measurements of the same gender and age. The Z score should be used for the diagnosis of osteoporosis in premenopausal women and men under 50 years of age. According to the World Health Organization's definition of bone mineral density: * A T score between -1 and -2.5 SD indicates osteopenia. * A T score below -2.5 SD indicates osteoporosis. * A T score below -2.5 SD accompanied by a fragility fracture(s) indicates severe osteoporosis. • A Z-score of -2.0 SD or lower is defined as "below the expected range for age,"
MORESJanuary 2021-January 2024The Male Osteoporosis Risk Prediction Score uses age, weight, and history of chronic obstructive pulmonary disease (COPD) to classify the risk of osteoporosis in men aged 50 and older. Values of 6 or higher are the threshold for screening.
OSTJanuary 2021-January 2024The Osteoporosis Self-Assessment Tool (OSA) screening program is used to improve osteoporosis screening in patients. The main tool of this screening program is the OS, a risk formula based on age and weight. OS has proven to be a reliable screening tool for osteoporosis in both female and male populations. The OS score is calculated using the formula: OST Score = \[Weight (kg) - Age\] x 0.2. Osteoporosis risk: * High risk: -20 to -4 for women, -20 to -1 for men * Moderate risk: -4 to -1 for women, -1 to 4 for men * Low risk: -1 to 20 for women, -4 to 20 for men

Countries

Turkey (Türkiye)

Contacts

PRINCIPAL_INVESTIGATORFatma Gül Ülkü Demir, MD

Kayseri City Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 9, 2026